Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2012 | short review

New developments in MDS

verfasst von: Michael Pfeilstöcker, MD, MBA, Reinhard Stauder, MD, MSc

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

The recent landscape of myelodysplastic syndrome (MDS) diagnosis and treatment is changing due to research resulting in a deeper insight into the pathobiology of the disease consequently being translated into new treatment approaches. Recent developments in MDS research published in the last year as well as data presented at ASH 2011 are covered in this review.
Vorheriger Artikel Brief update on recent developments in CML
Nächster Artikel ASH 2011—current developments in AML
Literatur
1.
Schecter J, Galili N, Raza A. MDS: refining existing therapy through improved biologic insights. Blood Rev. 2012;26(2):73–80.PubMedCrossRef
2.
Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727–36.PubMedCrossRef
3.
Stauder R, Nösslinger T, Pfeilstöcker M, et al. Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw. 2008;6(9):927–34 (Review).PubMed
4.
Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011 Jun 30;364(26):2496–506.
5.
Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011 Oct 13;365(15):1384–95.
6.
Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011 Dec 8;118(24):6239–46.
7.
Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011 Sept 11;478(7367):64–9.
8.
Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012 Jan 12;119(2):569–72.
9.
Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29;365(26):2497–506.
10.
Ebert B, Bernard OA. Mutations in RNA splicing machinery in human cancers. N Engl J Med. 2011 Dec 29;365(26):2534–5.
11.
Greenberg P. Oral presentation at ASH corporate friday symposia (Dec 2011): next-generation approaches for evaluation and treatment of myelodysplastic syndromes (MDS) sponsored by MDS Foundation.
12.
Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after mds derived from an international database merge. J Clin Oncol. 2012 Mar 10;30(8):820–9.
13.
Giagounidis A, Raza A, List AF, et al. Analysis of second primary malignancies in lenalidomide-treated patients with IPSS Low- or Int-1-Risk myelodysplastic syndromes. Blood. 2011 (ASH Annual Meeting Abtracts, abstr # 1704).
14.
Kuendgen A, Lauseker M, List AF, et al. Lenalidomide treatment is not related to AML progression risk but is associated with a survival benefit in RBC transfusion-dependent patients with IPSS Low- or Int-1-Risk MDS with del5q: results from a comparative study. Blood. 2011 (ASH Annual Meeting Abtracts, abstr # 119).
15.
Giagounidis A, Mufti GJ, Kantarjian HM, et al. Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (Int-1) risk myelodysplastic syndrome (MDS): results of a randomized, double-blind, placebo(PBO)-controlled study. Blood. 2011 (ASH Annual Meeting Abtracts, abstr # 117).
16.
Parikh AR, Yang Y, Wu CO, et al. Immunosuppressive treatment for patients with myelodysplastic syndromes: a review of 358 patients. Blood. 2011 (ASH Annual Meeting Abtracts, abstr # 1717).
17.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–32.
18.
Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987–96.PubMedCrossRef
19.
Itzykson R, Thépot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403–11.PubMedCrossRef
20.
Komrokji RS, Al Ali NH, Alrawi E, et al. Azacitidine for treatment of therapy related myelodysplastic syndrome. Blood. 2011 (ASH Annual Meeting Abtracts, abstr # 1712).
21.
Pleyer L, Stauder R, Burgstaller S, et al. Activity of azacitidine in 26 unselected, consecutive CMML patients included in the Austrian Azacitidine Registry (AAR) of the AGMT-study group. Blood. 2011 (ASH Annual Meeting Abtracts, abstr # 1715).
22.
Dimicoli S, Jabbour E, Borthakur G, et al. Phase II study of the histone deacetylase inhibitor panabinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Blood. 2011 (ASH Annual Meeting Abtracts, abstr # 1731).
23.
Sekeres MA, Komrokji RS, Lancet JE, et al. Final results from the phase 2 continuation study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes (MDS). Blood. 2011 (ASH Annual Meeting Abtracts, abstr # 607).
24.
Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. Haematologica. 2012 Mar 14. Epub ahead of print.
Metadaten
Titel
New developments in MDS
verfasst von
Michael Pfeilstöcker, MD, MBA
Reinhard Stauder, MD, MSc
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0036-x

Weitere Artikel der Ausgabe 3/2012

ASH update 2011: chronic lymphocytic leukemia and indolent lymphoma

  • short review

The End-of-Life in patients with glioma and their families

  • short review

Follow-up care for head and neck cancer patients

  • short review

Paraneoplastic neurologic disorders: a brief overview

  • short review

ASH 2011—Hodgkin’s disease and the high grade lymphomas

  • special report

Advanced neuroimaging techniques for diagnosis and treatment evaluation in neuro-oncology

  • short review